EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
- Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
The issuer is solely responsible for the content of this announcement. - Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
- The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
- Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.